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Abstract 
Objective: 
 The aim of this study was to determine the role of race as a significant risk factor 
for prediction of outcomes in heart failure (HF).  
Methods: 
 The data was collected on demographics, detailed history of HF, family history, 
vital signs, medication and laboratory profile for 585 patients from Heart failure 
Treatment Center of Emory University after year of 2000. Outcome of HF was defined as 
combination of death, placement of left ventricular assisted devise, heart transplant or 
emergency transplant. The independent relationship between race and outcomes of HF 
was evaluated by univariate and multivariate logistic regression analyses. The survival 
analysis was done by Cox regression modeling. 
Results: 
 Among 585 HF patients, 58.1% were whites and 41.9% were blacks and 28.2% 
HF patients had positive outcomes. Although Whites tended to have a more positive 
outcome (34.6%) than blacks (28.9%), the difference was not statistically significant. 
Factors predicting the outcome in whites were male gender (OR 5.02), history of 
hypertension (OR 2.3), ventricular arrhythmias (OR 2.4), placement of AICD(OR 0.09), 
low EF% (OR 0.95), high NYHA class (OR 3.25), use of beta blockers (OR 0.12), 
aldosterone blockers (OR 2.19), furosemide (2.18); while in blacks they were age in years 
(OR 0.96), history of PTCA (OR 7.04), dislipidemia (OR 3.90), depression (OR 0.01), 
placement of AICD (OR 0.14), low EF% (OR 0.92), systolic blood pressure (OR 0.96), 
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high NYHA class (OR 4.01), use of beta blockers (OR 0.14), torsemide (OR 2.86), and 
digoxin (OR 4.91) etc. Blacks had higher survival than whites (p < 0.001). 
 
Conclusion: 
 There is no significant difference in combined outcome (death, transplant, 
emergency transplant, and Left Ventricular Assisted Devise placement) of HF between 
whites and blacks. There are differences regarding the risk factors, which are more 
prominent in each race. Further exploration is required to evaluate the race as significant 
risk factor for predicting the outcome in HF.  
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Chapter I Introduction 
 
Definition of Heart Failure: 
Heart Failure (HF) is a condition in which heart is unable to pump sufficient 
blood for metabolizing tissues or can do so only from an abnormally elevated filling 
pressure (Kasper et el). From the point of hemodynamics, HF is defined as a 
pathophysiologic condition in which impaired cardiac performance is the cause for 
inability of the heart to increase cardiac output, at normal filling pressure to meet the 
metabolic demands of the body (Zevitz M. 2008). HF is considered as a syndrome with a 
variety of cardiac and systemic abnormalities.  
Annually more than 350, 000 people die because of sudden cardiac death and the 
major risk factor for this is heart failure with left ventricular systolic dysfunction (Thom, 
Haase et al. 2006) (Hernandez, Fonarow et al. 2007). HF affects 4.7 million people in 
United States and 550,000 new cases are added every year (East, Peterson et al. 2004). It 
is a leading cause of mortality, morbidity and hospitalization in individuals with age of 
65 years and older (Ruo, Capra et al. 2004). Furthermore, as the age advances the risk of 
HF will increase and the most growing population is geriatric population in the United 
States, so in upcoming years the number of patients with heart failure will be 
substantially increased (Ruo, Capra et al. 2004). All these explain why HF remains a 
significant public health concern and why the prediction of incident of HF and the 
prediction of HF outcomes are important fields of investigation.   
There are lots of causes and risk factors for development of HF. Risk factors can 
also be associated with development or progression of HF and some of them are 
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associated with both. Age and gender are consistently related to risk of development of 
HF; male gender and older age increases the risk significantly (McKee, Castelli et al. 
1971). In the United States, the major leading cause of systolic HF is coronary artery 
disease (Tsao and Gibson 2004). The other major cause  for HF is hypertension and it 
increases the risk of development of HF by two to three times (Chen, Vaccarino et al. 
1999). Without coronary artery disease the lifetime risk for development of HF in 
patients with hypertension is 1 in 9 men and 1 in 6 women (Lloyd-Jones, Larson et al. 
2002). In addition, patient with metabolic syndrome which consists of diabetes, 
hypertension, hyperlipidemia and obesity are at increased risk for development of HF. 
Diabetes alone is an important risk factor as it is also associated with ischemic heart 
disease and subsequent HF. Other independent risk factors are obesity, smoking, valvular 
heart disease, renal insufficiency, sedentary life style, left bundle branch block and family 
history of cardiomyopathy. (Tsao and Gibson 2004)  
There is always a question that whether race plays a role for variation in risk 
factor, etiology and outcome of heart failure. This is because studies have indicated that 
blacks were more likely to have noniscemic etiology and whites were more like to have 
ischemic etiology for HF (Thomas L. K. et al 2005). In addition, treatment for heart 
failure differs in these two races e.g. blacks are more likely to be on Angiotensin 
Converting Enzyme Inhibitors (ACEI) and Angiotensin Receptor Blockers (ARBs) 
because of more prevalence of hypertension in blacks and less likely to be on beta 
blockers because of low ischemic etiology for heart failure (Deswal, Petersen et al. 2006). 
Apart from that, Blacks are at high risk of having significant co-morbidities like obesity, 
hypertension, diabetes, renal disease, more severely reduced ejection fraction, which can 
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put them for worse outcome of heart failure (Thomas L. K. et al 2005). Studies have 
shown that Blacks have higher rates of hospitalization than Whites and also some studies 
have suggested that race is not an independent predictor of mortality in CHF (Carroll, 
Mulla et al. 2007). It has been suggested that African American patients with HF may 
have lower prevalence of Atrial Fibrillation than Caucasian (Vaccarino, Gahbauer et al. 
2002). Some studies have found higher risk of mortality in African American compared 
to Whites even after adjustment of other predictors of mortality, randomized treatment 
assignment, baseline imbalances between races and indicators of socioeconomic status 
(Mitchell E. J et al. 2005). According to some studies on renal transplant, in Blacks the 
most common etiologies for development of end stage renal disease are diabetes mellitus 
and hypertension. Many factors have been implicated for this finding including excess 
salt intake, genetic variation in drug response and socioeconomic factors which limits the 
access to health care (Flattery and Baker 2004).  Also studies have suggested that Blacks 
are less likely to be referred to renal transplant by their dialysis center (Wolfe 2003). 
According to surveys Blacks are less likely to be referred for kidney transplant than 
Whites (King, K. 2000). 
Because of aforementioned reasons, the exploration of the role of race as a 
significant risk factor for prediction of outcomes in HF is still important, so the aim of 
this study is to determine this relation.  
The questions which will be addressed are: 
1). Is there any difference in outcomes of HF between Whites and Blacks? 
2). Do the predictors of outcome vary between Whites and Blacks?  
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Chapter II Literature Review 
Mechanism of Heart Failure:  
The inciting event in development of HF is the inadequate adjustment of cardiac 
muscles to increased wall stress to maintain adequate cardiac output following injury to 
myocardium. Most important things for this adaptation are: 1) Frank-Starling Mechanism 
– increase in preload helps to maintain cardiac performance 2) Hypertrophy of cardiac 
myocytes with or without cardiac chamber dilatation; 3) Neurohumoral system 
activation, particularly norepinephrin release by cardiac adrenergic nerve endings, and 
the activation of rennin-angiotensin-aldosteron system (RAAS) help to maintain arterial 
pressure and perfusion to vital organs (Zevitz M., emedicine 2006).   
 
 
 
Figure 2.1. Pathophysiology for development of HF (Tsao and Gibson 2004) 
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Symptoms treatment and Outcome of Heart Failure: 
 The cardinal symptom of Heart Failure is Breathlessness. With increase in 
severity it manifests as exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, 
dyspnea at rest and acute pulmonary edema. Apart form this, patient also experiences 
fatigue and weakness because of poor perfusion of skeletal muscles. Because of poor 
perfusion of brain patient might complain of confusion, memory impairment anxiety, and 
headaches (Zevitz M., emedicine 2006).  
   Treatment for heart failure includes both nonpharmacologic and pharmacologic 
modalities. Nonpharmacologic measures are very important for successful management 
of heart failure. The first attempt is to further decrease the risk of recurrent cardiovascular 
injury with the control of hypertension, hyperlipidemia, diabetes, smoking cessation, 
weight reduction for obese patient, and participation in a well organized exercise program 
should be encouraged. Patients with HF are at risk for infection which can cause 
worsening of heart failure. Therefore, pneumococcus, influenza and hepatitis 
vaccinations are recommended in these patients (Tsao and Gibson 2004). 
 Various kinds of medications are available to treat congestive heart failure. Most 
of the patients receive multiple drugs for heart failure. Drugs for heart failure includes 
Angiotensin-converting enzyme inhibitors e.g. enalapril, lisinopril – they are the 
mainstay drug for heart failure which decreases the mortality. Other drug decreases 
mortality in heart failure patients is beta-blocker which also lowers the blood pressure 
and decreases the heart rate (Norgard and Stark 2008). Other drugs used in treatment of 
heart failure are diuretics, spironolactone, digoxin, nersitide. Diuretics have some 
mortality benefits according to some clinical trials (Pitt, Zannad et al. 1999). Apart from 
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heart failure medications, patients also receive nitrates for chest pain, calcium channel 
blocker to lower blood pressure and improve circulation, antiarrhythmics to prevent 
abnormal electric rhythm of the heart, and blood thinners to help prevent blood clots. In 
case of severe heart failure treatment by surgery and medical devise therapy are 
necessary. They are heart valve repair or replacement, coronary bypass surgery, heart 
transplant, ventricular assisted devise placement, cardiac pacemakers, and defibrillators. 
(Mayo clinic 2008). 
 Different studies have taken different measures as outcome of HF. Some studies 
have taken the outcome as death, rehospitalization, in hospital complication rates 
including myocardial infarction, admission to coronary care unit or intensive care unit 
(ICU), renal failure, hypotension, shock and the need for mechanical ventilation (Bhatia, 
Tu et al. 2006). Study by Smith et al. has taken clinical outcomes of heart failure as 
death, decline in functional status and readmission to hospital due to cardiac reasons 
(Smith, Masoudi et al. 2003). Myers et al. study has taken his end point for heart failure 
as cardiac related mortality. In his study two other end points also has been studied and 
they are cardiac transplantation and left ventricular assisted devise placement (Myers, 
Arena et al. 2008).  
 The studies on heart failure and outcome suggest that, more often, Black patients 
have hypertension, diabetes, renal insufficiency, more symptomatic heart failure by New 
York Heart Association (NYHA) HF classification. Also Blacks have low ischemic 
etiology for heart failure and less previous percutaneous coronary intervention or 
coronary artery bypass grafting. Where as Whites have more myocardial infarction as 
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etiology for heart failure and multi vessels coronary artery disease (Thomas, East et al. 
2005).  
 Study suggests that Black patients with mild to moderate left ventricular 
dysfunction are at high risk for progression to severe heart failure and death from any 
cause than White patients with similar type of left ventricular dysfunction (Dries, Exner 
et al. 1999). Studies also suggest that the higher mortality in Black patients than in White 
patients have been due to differences in severity and cause of heart failure, more 
prevalence of coexisting conditions in Blacks, socioeconomic and cultural factors, and 
access to high quality medical care (1990; Alexander, Grumbach et al. 1995). Some of 
the studies suggest higher mortality in Blacks with heart failure. However, recent 
statewide study on hospital discharge data on congestive heart failure patient suggests 
lower case fatality rate in Blacks than their counter part (Philbin and DiSalvo 1998). 
 A recent study on heart failure prognosis by race and etiology has taken the 
outcome of heart failure as death or rehospitalization or both. In this study there is no 
significant difference in unadjusted and adjusted mortality rates in whites and blacks at 
the end of 1 and 5 years. In this study mortality rates are also examined by ischemic and 
nonischemic etiology which shows that at the end of 5 years, mortality rate is different in 
nonischemic left ventricular systolic dysfunction e.g. Blacks have higher mortality rate 
compare to Whites. Also this study has suggested several variables predictive of decrease 
survival in patients with left ventricular systolic dysfunction including renal 
insufficiency, diabetes, history of connective tissue disease, valvular disease, and 
peripheral vascular disease. Also in this study there are two other predictors for 
  
20
20
rehospitalization and they are renal disease and ischemic etiology of heart failure 
(Thomas, East et al. 2005).  
 A study by Mathew et al. suggest that Blacks have higher risk for 
rehospitalization than Whites but the reason for this finding is not clear. They suggested 
that cardiomegaly and diabetes have quantitatively different effect in both the races. This 
study also suggest that difference in morbidity of HF in Blacks and Whites are more 
likely due to difference in other co-morbid conditions such as diabetes, hypertension etc., 
socioeconomic factors such as attitudes, access to health care; difference in lifestyle and 
psychological factors like depression, stress; and not due to biological differences.  
 Renal impairment is a critical risk factor for outcome measure in HF patients 
because renal impairment increases the risk for death and rehospitalization (Smith, 
Vaccarino et al. 2003). A study on race and renal impairment in HF suggests that Whites 
with impaired renal function have greater risk for death than Blacks with renal 
impairment (Smith, Shlipak et al. 2005). According to Carson et al. HF is associated with 
poor prognosis in Blacks than in Whites. This study was aimed to determine the racial 
difference in response to treatment for HF. This study suggested that combination of 
hydralazine and isosobide dinitrate combination is associated with reduction in mortality 
in Black patients with HF. The ACE inhibitors are not much effective in these patients 
because of less active rennin-angiotensin system in Blacks (Carson, Ziesche et al. 1999).  
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Chapter III Methodology 
 
Study Design: 
 As described earlier in the introduction, this study was conducted with the aim to 
describe the racial differences in the outcomes and the predictors of outcomes in patients 
with HF. This is a retrospective cohort study design.  
Data Collection and Variable definition:  
 All patients seen by Heart Failure Treatment Center of Emory University after 
year of 2000 are included in this study. Inclusion criteria for this study were 1) age ≥18, 
2) patients should have systolic HF, 3) ejection fraction ≤ 45 documented within 6, 
months of evaluation,  4) Patients should be on optimal therapy for HF e.g. on beta 
blocker, ACE inhibitors, aldosterone receptor blocker, diuretics, 5) New York Heart 
Association class II-IV  
Based on these criteria, data was collected for 606 patients. Out of these, 18 
patients were excluded from the study because of non-white, non-black race. All data was 
collected from the hospital and the HF clinic electronic databases. Data regarding 
patient’s age, sex, race, etiology for HF, history of myocardial infarction, coronary artery 
bypass, angioplasty, atrial arrhythmias, ventricular arrhythmias, placement of cardiac 
devices like biventricular pacemakerr, defibrillator or both, other co- morbidities like 
diabetes, hypertension, dyslipidemia, chronic lung diseases, sleep apnea, thyroid disorder, 
depression, cerebrovascular accident, malignancy, history of smoking and alcohol 
consumption was collected.  Also, data was recorded for family history of premature 
ischemic heart disease and idiopathic dilated cardiomyopathy. Index date was determined 
as the first available date after year of 2000 where the patients were stable, on optimal 
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medical treatment and most of the laboratory tests were available (Deswal, Petersen et al. 
2006). On the evaluation date, data was collected on height, weight, ejection fraction, 
NYHA class, heart rate, systolic blood pressure, diastolic blood pressure, and patient’s 
medications. The categories of collected medications were ACE inhibitors, Angiotensin 
Receptor Blockers (ARB), beta blockers, statins, ezetimibe, allopurinol, aldosterone 
blocker,diuretics ( bumetanide, furosemide, torsemide, metolazone, hydrochlorthiazide), 
digoxin, aspirin, clopidogrel, oral nitrates, calcium channel blockers, antiarrhythmics, 
non-steroidal anti-inflammatory agents, warfarin, antidepressants, antianxiety agents, and 
antidiabetic medications. In addition data on  patient’s laboratory tests such as White 
Blood Cell count, Red Blood Cell count, hemoglobin, hematocrit, Red Cell Distribution 
Width (RDW), platelet, mean platelet volume, lymphocyte percentage, blood metabolic 
profile, cardiac enzymes, serum lipid profile, and thyroid stimulating hormone.    
 Study outcome was defined as a combination of death, placement of left 
ventricular assisted device, emergency heart transplant and transplant, while survival 
period was defined as the time period between the patient’s index date and the patient’s 
last follow up visit. Left Ventricular assisted devise is a mechanical devise that is 
implanted surgically. It helps to maintain the ability of the heart to pump blood. It is used 
in people waiting for heart transplantation, so it is also known as “bridge to transplant. 
For analysis purposes, the etiology of HF was defined as either ischemic or non-ischemic 
cause. Non-ischemic causes are characterized the following conditions: idiopathic dilated 
cardiomyopathy, hypertensive cardiomyopathy, cardiomyopathy because of valvular 
heart disease, post partum cardiomyopathy, cardiomyopathy due to chemotherapy, and 
myocarditis. According to New York Heart Association, symptoms of HF was 
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categorized into four classes: Class I patients with no limitation of activities; they suffer 
no symptoms from ordinary activities, Class II patients with slight, mild limitation of 
activity; they are comfortable with rest or with mild exertion, Class III patients with 
marked limitation of activity; they are comfortable only at rest, Class IV patients who 
should be at complete rest, confined to bed or chair; any physical activity brings on 
discomfort and symptoms occur at rest (2009).  Recent smoking was defined as smoking 
during the last two years but not currently smoking and former smoking was defined as 
quitting smoking two years before the index date. Former alcohol consuming was defined 
as quitting alcohol consumption two years before the index date. As chronic lung diseases 
was consider Chronic Obstructive Lung Disease, asthma, and restrictive lung disease e.g. 
pulmonary fibrosis, sarcoidosis.  
Statistical Analysis: 
 The demographics, clinical characteristics, treatment, and laboratory values of 
patients with HF were compared in Whites and Blacks and in patient subgroups with 
positive outcome and no outcome. In addition both combined outcome and each 
component of the outcome were compared in Whites and Blacks. Chi-square test was 
used for dichotomous variables and student’s t-test was used for continuous variable 
(Bhatia, Tu et al. 2006). In this study missing laboratory values were imputed using mean 
values of the cohort study for that parameter (Deswal, Petersen et al. 2006). 
 Univariate logistic regression analysis was performed to identify which variables 
were associated with the outcome of HF in each group e.g. Blacks and Whites. This was 
done individually in Whites and Blacks without doing comparison in between these 
groups. This analysis was done using all the variables mentioned above.  
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 Finally, multivariate logistic regression analysis was performed to determine 
which variables affect the outcome in Whites and Blacks. It was performed by using 
backward analysis method. Risk adjustment was done by controlling simultaneously for 
covariates used in univariate analysis. The aim of this analysis was to find all the factors 
which affect the outcome of HF in Whites and Blacks. Some of the variables were 
eliminated from the analysis because in one group their values were less than 5 and so 
cannot perform logistic regression and they were weight, height, diastolic blood pressure, 
history of thyroid disease, atrial arrhythmias; in the drugs they were ezetimibe, 
bumetanode, clopidogrel, oral nitrates, NSAIDS, anti-anxiety, Sulfonylurea, Biguanide, 
Thiazolidinedine; in the laboratory variables some of them were uric acid, Beta 
natriuretic peptide, total cholesterol, triglycerides, low density lipoprotein (LDL), high 
density lipoprotein (HDL)etc. In both univariate and multivariate analyses, first variable 
was taken as reference value e.g. female in gender, no smoking in smoking, no history of 
sleep apnea in History of sleep apnea etc. 
 Cox regression analysis was performed to evaluate the survival in White and 
Black patients with HF.  Survival curve was also constructed.  
 The statistical analysis was done with Statistical Package for Social Science 
(SPSS) for windows version 16. 
 
 
 
 
 
  
25
25
Chapter IV Results 
 Data of 585 patients were analyzed. Out of these, 340 patients were Whites and 
245 patients were African Americans. The study outcome was observed in 165 patients 
with HF. Clinical characteristics, which were statistically significant between Whites and 
Black, described in Table 1. Whites have higher proportion of male, lower proportion of 
former smokers, more ischemic etiology for HF, history of myocardial infarction, history 
of PTCA and CABG, dyslipidemia, and EF% compared to blacks. However, blacks were 
younger, more female population, more current smokers, high proportion of non-
ischemic cause for heart failure, hypertension, history of CVA, and family history of 
dilated cardiomyopathy, high heart rate, systolic BP, and low EF% compared to whites. 
Appendix 1  shows all the other findings of the clinical variables which also include the 
findings of table 1.  
In Table 2 are shown the medication and laboratory characteristics; those are 
statistically significant for white and black patients with HF; all the values are shown in 
Appendix 2. Whites were using more ACE inhibitors, statins, antidepressants, and 
antianxiety medications; while blacks were using more aldosterone blockers. Whites had 
higher level of hemoglobin, serum potassium, and triglyceride and blacks had high level 
of platelets, mean platelet volume, serum sodium, uric acid, and HDL.  
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Table 1. Clinical Characteristics of Heart Failure in Whites and Blacks. 
Variable Whites Blacks P-value 
Gender 
Male 
Female 
 
75.9% 
24.1% 
 
56.7% 
43.3% 
<0.001 
 
Smoking 
Never Smoke 
Smoker 
Former Smoker 
 
44.9% 
18.9% 
36.1% 
 
51.0% 
23.8% 
25.2% 
<0.05 
Primary Cause of HF 
Ischemic 
Non-Ischemic 
 
52.1% 
47.9% 
 
 
22.3% 
77.7% 
<0.001 
History of Myocardial Infarction 
Yes 
No 
 
46.2% 
53.8% 
 
20.3% 
79.7% 
<0.001 
History of CABG 
Yes 
No 
 
31.0% 
69.0% 
 
9.6% 
90.4% 
<0.001 
History of PTCA 
Yes 
No 
 
21.9% 
78.1% 
 
9.6% 
90.4% 
<0.001 
Hypertension 
Yes 
No 
 
52.5% 
47.5% 
 
75.7% 
24.3% 
<0.001 
Dislipidemia 
Yes 
No 
 
54.8% 
45.2% 
 
39.6% 
60.4% 
0.001 
History of CVA 
No 
Yes 
 
87.2% 
12.8% 
 
80.4% 
19.6% 
<0.05 
F/H of Dilated Cardiomyopathy 
No 
Yes 
No Mention 
 
75.5% 
5.0% 
19.4% 
 
70.0% 
12.2% 
17.3% 
<0.05 
Age 55.68±11.39 49.22±13.21 <0.001 
Height (Inches) 69.83±3.58 66.93±3.95 <0.001 
Heart Rate at visit 74.59±12.85 79.89±15.85 <0.001 
Systolic BP 113.32±19.12 119.06±19.32 <0.001 
EF% 21.50±11.17 17.89±9.4 <0.001 
 
 
 
  
27
27
Table 2. Drugs and Laboratory profiles in Whites and Blacks 
Variable Whites Blacks P-value 
ACE-I 75.0% 66.1% <0.05 
Statin 54.7% 34.0% <0.001 
 
Aldosteron Blocker 
38.6% 50.6% <0.01 
Antidepressant 36.0% 18.6% <0.05 
Antianxiety 20.0% 4.7% <0.05 
Hgb 13.64±2.66 12.97±1.80 0.001 
Platelet(×10E3) 228.97±71.98 251.49±87.08 0.001 
Mean Platelet Volume 8.72±1.06 9.26±1.09  0.01 
Lymphocyte% 23.40±7.8 26.45±9.02 <0.001 
Na+ 137.24±3.22 137.99±3.1 <0.01 
K+ 4.15±0.54 3.95±0.49 <0.001 
Uric Acid 8.3±0.88 8.5±1.1 <0.05 
BNP 649.51±845.86 981.37±1171.99 <0.05 
Triglyceride 168.49±138.24 114.79±132.50 <0.001 
HDL 38.67±12.27 44.65±13.67 0.099 
 
In Table 3 are shown the clinical characteristics in patients with outcome and 
those without outcome. In this table only statistically significant variables are described 
and all the clinical characteristics are described in Appendix 3. Patients with adverse 
outcome of HF had more males, high never consumers of alcohol and former consumers 
of alcohol, high proportion of ischemic cause for HF, never users of CPAP, 
hypothyroidism, depression, atrial tachycardia, ventricular arrhythmias, high heart rate, 
NYHA class, and low EF%. Patients with better outcome of HF had more females, high 
current consumers of alcohol, high proportion of non ischemic cause for HF, history of 
sleep apnea, use of CPAP, no thyroid disorders, no depression, family history of dilated 
cardiomyopathy, paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular 
tachycardia, use of AICD, high systolic BP, and EF%.  
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Table 3. Clinical Characteristics by Outcome of Heart Failure. 
Variable Outcome 
Positive 
Outcome 
negative 
P-value 
Gender 
Male 
Female 
 
75.2% 
24.8% 
 
65.6% 
34.4% 
<0.05 
Alcohol Consumption 
No Drinker 
Drinker 
Former Smoker 
 
65.2% 
20.0% 
14.8% 
 
55.6% 
32.8% 
11.6% 
<0.05 
Primary Cause of Heart Failure 
Ischemic 
Non-Ischemic 
 
46.0% 
54.0% 
 
 
37.2% 
62.8% 
 
<0.05 
History of Sleep Apnea 
No 
Yes 
No Mention 
 
75.8% 
14.3% 
9.9% 
 
80.9% 
18.0% 
1.2% 
<0.001 
History of CPAP 
No 
Yes 
No Mention 
 
82.4% 
6.9% 
10.7% 
 
87.9% 
10.9% 
1.2% 
<0.001 
Thyroid Disorder 
No Disorder 
Hyperthyroidism 
Hypothyroidism 
 
78.2% 
17.3% 
4.5% 
 
82.5% 
17.5% 
0% 
<0.01 
Depression 
No 
Yes 
No Mention 
 
66.2% 
27.5% 
6.2% 
 
78.5% 
20.3% 
6.2% 
<0.01 
F/H of Dilated Cardiomyopathy 
No 
Yes 
No Mention 
 
76.6% 
8.9% 
14.67% 
 
64.9% 
9.4% 
25.7% 
<0.05 
Atrial Arrhythmias 
No Atrial Arrhythmias 
Paroxysmal Atril 
Fibrillation/Flutter 
Chronic Atrial 
Fibrillation/Flutter 
Atrial Tachycardia 
Paroxysmal Supraventricular 
Tachycardia 
No Mention 
 
 
59.9% 
14.8% 
 
19.1% 
 
3.1% 
0% 
 
3.1% 
 
48.6% 
17.8% 
 
19.7% 
 
1.2% 
5.8% 
 
6.9% 
<0.01 
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Ventricular Arrhythmias 
No  
Yes 
No Mention 
 
43.2% 
53.1% 
3.7% 
 
50.2% 
41.0% 
8.8% 
<0.05 
AICD 
No 
Yes 
 
78.3% 
21.7% 
 
66.5% 
33.5% 
<0.01 
Heart Rate at visit 79.74±15.61 76.22±13.13 <0.05 
Systolic BP 110.92±19.68 116.25±18.67 <0.01 
NYHA at Visit 2.80±0.72 2.37±0.63 <0.001 
EF% 17.05±8.87 19.77±9.03 <0.01 
 
 Table 4 shows the medication and laboratory profile of patients regarding the 
outcome subgroups. In this table, only statistically significant variables are described and 
all the variables are described in appendix 4. Patients with adverse outcome of HF were 
using less beta blockers, more aldosterone blockers, torsemide, digoxin, antiarrhythmics; 
while the patients with better outcome were using more beta blocker and 
thiazolidinediones. Adverse outcome of HF patients had high serum BUN, and creatinine 
patients with better outcome of HF had high platelet count, lymphocyte%, high serum 
sodium, BNP and triglyceride.    
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Table 4. Drugs and Laboratory Profile for Outcome of Heart Failure Patients. 
Variable Outcome 
Positive 
Outcome 
negative 
P-value 
Beta-Blocker 76.4% 95.1% <0.001 
Aldosteron Blocker 51.5% 41.3% <0.05 
Torsemide 34.5% 17.5% <0.001 
Digoxin 66.7% 44.5% <0.001 
Antiarrhythmics 38.8% 27.3% <0.01 
Thiazolidinedione 0% 10.3% <0.05 
Platelet(×10E3) 229.22±71.84 244.42±85.01 <0.05 
Lymphocyte% 21.85±8.15 25.40±7.44 <0.001 
Na+ 136.5±3.21 138.03±3.1 <0.001 
BUN 25.80±13.87 21.38±16.81 <0.01 
Creatinine 1.58±1.38 1.30±0.72 <0.05 
Uric Acid 8.4±1.69 8.4±0.43  
BNP 1.32±1331.61 6.5±843.57 <0.001 
Triglyceride 123.25±73.45 155.29±158.65 <0.05 
 
   Table 5 presents the differences in combined outcome and each component of the 
outcome between Whites and Blacks. According to this table, 34.6% of Whites and 
28.9% of Blacks had positive outcome, but this difference is not statistically significant.  
A percentage of 18.3% of Whites had died while a 22.9% of Blacks had died. Although 
Blacks had more death than Whites, this difference is not statistically significant. 
Moreover, a percentage of 0.9% of Whites and a percentage of 0.4% of Blacks had 
placement of left ventricular assisted devise and this is not statistically significant, while 
a percentage of 12.6% of Whites and a percentage of 6.5% of Blacks had received heart 
transplant which is statistically significant. A 3.3% of Whites and a 2.8% of Blacks had 
received emergency heart transplant as a treatment of HF, which is not statistically 
significant.   
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 Table 5. Outcome of Heart Failure by Race 
Variables White Black P-value 
Outcome 34.6% 28.9% 0.16 
Death 18.3% 22.9% 0.17 
VAD 0.9% 0.4% 0.49 
Transplant 12.6% 6.5% <0.05 
Emergency 
Transplant 
3.3% 2.8% 0.70 
 
 
 Table 6 shows the relationship of individual variables and outcome in Whites and 
Blacks. Factors decreasing the risk for adverse outcome and statistically significant were 
male (OR0.44), former smokers (OR 0.45), former consumers of alcohol (OR 0.38), 
history of CPAP use (OR 0.12), aldosterone blockers (OR 0.53), torsemide (OR 0.46), 
digoxin (OR 0.53), antiarrhythmics (OR 0.48), lymphocyte% (OR 0.89), and serum 
sodium (OR 0.87); while factors increasing adverse outcome and statistically significant 
were history of ventricular arrhythmias (OR 1.34), high NYHA class (OR 2.48), use of 
beta blockers (OR 6.28), and high serum BUN (OR 1.02).  Factors decreasing the risk of 
adverse outcome and statistically significant were age (OR 0.96), use of CPAP (OR 
0.08), high EF% (OR 0.91), high systolic BP (OR 0.97), use of beta blockers (OR 5.46), 
torsemide (OR 0.31), digoxin (OR 0.23), and serum sodium (OR 0.85). Factors 
increasing adverse outcome and statistically significant were history of hypertension (OR 
3.16), ventricular arrhythmias (OR 3.47), NYHA class (OR 2.81), use of beta blockers 
(OR 5.46), furosemide (OR 2.19), and serum uric acid (OR 1.57).       
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Table 6. Relationship of Individual Variables and Outcome of HF by White and 
Black. 
Variable Whites 
OR                   CI 
Blacks 
OR                        CI 
Age (Yr) 1.006              0.98-1.02 0.965              0.943-0.987 
Gender 
Male 
 
0.44                0.230-0.844 
 
0.937              0.522-1.68 
Smoking 
Smoker 
Former Smoker 
 
0.721              0.40-1.28   
0.455              0.22-0.93 
 
0.955              0.460-1.98 
1.03                0.446-2.40 
Alcohol 
Drinker 
Former Drinker 
 
1.02               0.46-2.28 
0.38               0.15-0.97  
 
0.764              0.30-1.89 
0.605              0.22-1.64 
Primary Cause of HF 
Ischemic 
Idiopathic 
 
1.34               0.56-3.17 
0.82               0.33-2.05 
 
0.62                0.25-1.53 
0.48                0.22-1.03 
History of Myocardial 
Infarction 
0.781             0.47-1.27 0.98                0.47-2.04 
History of CABG 1.40               0.81-2.40 0.82                0.31-2.16 
History of PTCA 1.09               0.60-1.98 0.63                0.24-1.64 
Hypertension 0.69               0.41-1.16 3.16                1.59-6.26 
Diabetes 0.85               0.49-1.46 1.25                0.67-2.33 
Dislipidemia 0.92               0.55-1.56 0.69                0.37-1.30 
History of Sleep Apnea 
Yes 
No Mention 
 
0.11               0.02-1.54 
0.11               0.02-0.61 
 
0.10                0.01-1.93 
0.007              0.00-0.68 
History of CPAP 
Yes 
No Mention 
 
0.12               0.02-0.56 
0.09               0.01-0.54 
 
0.08                0.01-0.74 
0.04               0.00-0.49          
History of Depression 
Yes 
No mention 
 
0.19                0.03-1.01 
0.25                0.04-1.35 
 
0.11                 0.01-1.04 
0.26                 0.02-2.69 
 
History of CVA 1.61                 0.69-3.74 0.40                  0.18-1.87 
History of Malignancy 0.33                 0.14-1.76 1.39                  0.46-4.15 
Family h/o premature 
ICM 
Yes 
No Mention in the history 
 
1.82                 0.92-3.59 
2.69                 0.19-6.17 
 
1.44                  0.63-3.32 
1.50                  0.53-4.17 
Family History of DCM 
Yes 
No Mention 
 
2.36                 0.19-4.70 
2.71                 0.80-9.13 
 
1.75                  0.75-4.08 
1.21                  0.37-3.91 
Atrial Arrhythmias 
Paroxysmal atrial 
 
2.57                 0.66-9.99 
 
3.04                  0.62-14.82 
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Fibrillation 
Chronic Atrial 
Fibrillation 
Atrial Tachycardia 
 
 
2.31                 0.54-9.90 
1.71                 0.41-7.07 
4.50                 0.49-41.24 
 
 
1.31                  0.22-7.54 
3.09                  0.55-17.16 
9.00                  0.52-155.24   
History of Ventricular 
Arrhythmia 
Yes 
No mention 
 
 
1.34                 0.39-4.57 
2.37                 0.70-8.00 
 
 
3.47                  0.73-16.48 
4.04                  0.84-19.43     
Device 1.62                 0.94-2.77 1.26                  0.69-2.29 
AICD 1.54                 0.87-2.72 2.23                  0.12-4.44 
BivPaceAICD 1.39                 0.83-2.30 0.95                  0.51-1.76 
BivPace 0.35                 0.06-1.92 0.50                  0.03-6.43 
Height(In) 0.99                 0.85-1.16 1.49                  1.00-2.23       
Weight (LB) 0.99                 0.98-1.00 1.00                  0.98-1.02 
EF% 0.98                 0.95-1.00 0.91                  0.86-0.95 
Heart Rate  1.01                 0.99-1.03 1.03                  1.00-1.05 
Systolic BP 0.99                 0.98-1.01 0.97                  0.95-0.98 
Diastolic BP 1.01                 0.95-1.06 0.93                  0.84-1.02 
NYHA class 2.48                 1.66-3.71 2.81                  1.74-4.53 
ACE Inhibitors 0.92                 0.52-1.63 1.51                  0.82-2.75 
ARB 1.11                 0.59-2.08 0.73                  0.38-1.42 
Beta-Blocker 6.28                 2.88-13.69 5.46                  2.06-14.43 
Statin 0.90                 0.55-1.46 1.57                  0.82-2.98 
Allopurinol 0.72                 0.30-1.68 0.69                  0.19-2.46 
Aldosterone Blocker 0.53                 0.32-0.87 0.81                  0.45-1.45 
Furosemdie 0.91                 0.55-1.49 2.19                  1.21-3.97 
Torsemide 0.46                 0.25-0.82 0.31                  0.16-0.59 
Metolazone 0.62                 0.24-1.68 0.37                  0.12-1.12 
Hydrochlorothiazide 0.43                 0.14-1.33 3.81                  0.47-30.73 
Digoxin 0.53                 0.32-0.88 0.23                  0.12-0.46 
Aspirin 0.46                 0.14-1.54 0.37                  0.06-2.14 
Calcium Channel 
Antagonist 
0.21                 0.09-1.49 2.14                  0.78-5.90 
Antiarrhythmics 0.48                0.28-0.79 0.86                  0.45-1.63 
Warfarin 0.75                0.23-2.42 1.68                  0.32-8.75 
Antidepressant 1.52                0.46-4.97 1.10                  0.06-20.01 
Insulin 3.00                0.45-19.92 0.50                  0.03-6.43 
Other drugs 2.12                0.49-9.07 0.58                   0.09-3.50 
WBC (10E3) 1.06                0.96-1.17 0.98                   0.85-1.12 
RBC (10E6) 0.48                0.13-1.68 0.52                   0.16-1.70 
RDW 1.06                0.83-1.37 1.11                   0.588-2.12 
HgB 1.01                0.90-1.13 0.98                   0.84-1.15 
Hct 0.96                0.92-1.00 1.02                   0.97-1.08 
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PLT (10E3) 0.99                0.99-1.00 0.99                   0.99-1.00 
Mean Platelet volume 1.22                0.69-2.14 1.64                   0.59-4.54 
Lymphocyte 0.89                0.85-0.93 0.98                   0.95-1.02 
Na 0.87                0.80-0.94 0.85                   0.77-0.94 
K 0.81                0.52-1.27 0.98                   0.54-1.77 
CO2 1.22                0.95-1.57 0.90                   0.68-1.19 
Glucose 1.00                0.99-1.00 0.99                   0.98-1.00 
BUN  1.02                1.00-1.04 1.01                   0.99-1.02 
Creatinine 1.38                0.97-1.96 1.37                   0.99-1.88 
Protein total 0.80                0.28-2.28 1.44                   0.26-7.97 
Albumin 0.28                0.03-2.34 0.91                   0.70-11.81 
Uric Acid 0.56                0.38-1.81 1.57                   1.07-2.29 
Total Cholesterol 1.001              0.99-1.008 0.99                   0.98-1.001 
Triglyceride 0.99                0.99-1.00 0.99                   0.99-1.002 
HDL 0.99                0.92-1.07 0.68                   0.39-1.18 
LDL 1.00                0.98-1.02 0.99                   0.96-1.01 
TSH 1.11                0.93-1.33 0.97                   0.92-1.03 
BNP 1.00                1.00-1.001 1.00                   1.00-1.001 
 
Yellow highlight indicates the statistical significance. 
 
Table 7 represents the multivariate logistic regression analysis of all the variables 
with HF outcome in White and Black patients. Factors significantly predict the outcome 
in Whites were males (OR 5.02), history of hypertension (OR 2.30), history of sleep 
apnea (OR 1.85), ventricular arrhythmia (OR 2.40), AICD (OR 0.09), EF% (0.95), 
NYHA class (3.25), use of beta blockers (OR 0.12), aldosterone blockers (OR 2.19), 
furosemide (OR 2.18), lymphocyte% (OR 0.70), serum BUN (OR 0.94). For Blacks they 
were age in years (OR 0.96), history of PTCA (OR 7.04), dyslipidemia (OR 3.90), 
depression (0.01), AICD (0.14), EF% (OR 0.92), systolic BP (OR 0.96), NYHA class 
(4.01), use of beta blockers (OR 0.14), torsemide (OR 2.86), digoxin (OR 4.91), WBC 
(OR 0.03), hemoglobin (0.00), hematocrit (OR 1.87), and lymphocyte% (OR 0.47). 
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Table 7. Relationship of individual variables with HF Outcome in Whites and 
Blacks in a multivariate model. 
 
Variable Whites 
OR                   CI 
Blacks 
OR                        CI 
Age (Yr) - 0.96              0.92-1.00 
Gender 
Male 
 
  5.02            1.71-14.68 
- 
 
History of PTCA - 7.04            1.16-42.61 
Hypertension   2.30            1.08-4.90  
Dislipidemia - 3.90            1.21-12.55 
History of Sleep Apnea 
Yes 
No Mention 
 
  1.85            0.68-5.01 
  26.66          1.64-43.46 
- 
History of CPAP 
Yes 
No Mention 
- - 
History of Depression 
Yes 
No mention 
-  
0.01              0.00-0.37 
0.03              0.00-0.92 
History of Ventricular 
Arrhythmia 
Yes 
No mention 
 
 
 2.40             1.06-5.45 
 0.37             0.06-2.29 
- 
AICD  0.09             0.03-0.28 0.14            0.04-0.49 
EF%  0.95             0.91-0.99 0.92            0.86-1.00 
Systolic BP - 0.96            0.94-0.99 
NYHA class  3.25              1.78-5.95 4.01            1.72-9.32 
Beta-Blocker  0.12              0.05-0.28 0.14            0.04-0.43 
Aldosterone Blocker  2.19              1.22-3.38 - 
Furosemdie  2.18              1.03-4.58 - 
Torsemide - 2.86            1.42-5.74 
Digoxin  4.91            2.37-10.15 
WBC (10E3) - 0.03            0.00-1.72 
HgB - 0.00            0.0-13.48 
Hct - 1.87            0.43-8.33 
Lymphocyte  0.70               0.52-1.94 0.47            0.21-1.05 
BUN   0.94               0.86-1.02 - 
 
 
 
I 
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 Figure 4.1 represents the survival analysis by Cox regression model. As you can 
see 
 
Figure 4.1 Survival analysis for HF patients in whites and blacks (P<0.001) 
 
In this figure, Blacks have higher survival than Whites at the end of 2500 days. Also, the 
curve is steep for Whites than Blacks. The difference is statistically significant as the p-
value is <0.001. 
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Chapter V Discussion 
 This is a retrospective cohort study examining the differences in the outcome of 
HF and predictors of HF outcome in Whites and Blacks. This study suggests that there is 
no significant difference in the combined outcome of HF even when each component of 
the outcomes was checked. However, an exception was observed regarding heart 
transplant as there was a statistically significant difference in transplant between Whites 
and Blacks. Generalizing this finding about the outcome might be tricky as the power is 
0.42 which is not strong enough for something like this. There are studies describes the 
difference of renal transplant in between Whites and Blacks (Flattery and Baker 2004). 
One of these studies has shown that Blacks are less likely to be referred for the renal 
transplantation by their dialysis center and this could be due to poor antigen matching, 
unfavorable socioeconomic factors and immunological differences. Furthermore, Black 
patients are less likely to find living identical donors than Whites. The socioeconomic 
disadvantage is best represented by outcome based on insurance provider. Those who 
have private insurance are tend to survive more (Flattery and Baker 2004). This study 
could explain the difference in the transplant and HF outcome in Whites and Blacks. 
There is also a study suggests that after heart transplantation Blacks have higher overall 
rejection and hospitalization rates. (Pamboukian, Costanzo et al. 2003) 
 From the univariate analysis the factors which are important for predicting the 
outcomes in Whites are male gender, former smoker, former alcohol users, history of 
sleep apnea, history of CPAP users, high NYHA class, use of beta blocker, aldosterone 
blockers, torsemide, digoxin, and antiarrhythmics, high percentage lymphocyte count, 
high serum sodium, high serum BUN, and low serum uric acid levels. However the 
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predicted factors in Blacks are age, history of hypertension, sleep apnea, and CPAP use, 
AICD placement, height, EF%, systolic blood pressure, and NYHA class, use of beta 
blockers, furosemide, torsemide, digoxin, sodium and uric acid and there are some 
differences compared to Whites. Thus, from this analysis we can say that some of the 
variables are different between the Black and White races regarding prediction of 
outcome. 
 This study suggested that Blacks who develop HF are younger compared to 
Whites and they also receive heart transplant at younger age than Whites (Pamboukian, 
Costanzo et al. 2003; Flattery and Baker 2004). Furthermore, blacks tend to have more 
hypertension and diabetes than Whites and according to United States renal data system 
(1999) African Americans have highest rate of hypertension, so hypertension is an 
important risk predictor for Blacks. In Whites, male gender has worst outcome which 
might be due to predominant male population in this dataset. Also, in Whites, have left 
smoking and alcohol consumption has low risk for positive outcome. Alcohol 
consumption is associated with direct myocardial toxicity and risk for hypertension 
development. So former alcohol consumption is associated with more adverse 
outcome.(Marmot, Elliott et al. 1994) Smoking is associated with oxidative stress, 
endothelial dysfunction and insulin resistant which can lead to worst outcome. However, 
patients with history of past smoking seem to have lower risk for adverse outcome 
(Gvozdjakova, Kucharska et al. 1992). There is a study demonstrating that sleep apnea 
leads to adverse hemodynamic, autonomic and inflammatory consequences in both 
Whites and Blacks patients with ischemic cardiomyopathy, but not in non ischemic 
cardiomyopathy and leads to worse outcome in patients with HF (Yumino, Wang et al. 
  
39
39
2009). It has been postulated that AICD reduces mortality in patients with HF due to 
reduced left ventricular function. Also several studies suggest that Blacks have lower rate 
of AICD placement than Whites, so according to these studies AICD reduces the adverse 
outcome in Blacks (Bardy, Lee et al. 2005; Hernandez, Fonarow et al. 2007). This study 
was conducted on patients with systolic HF with very low ejection fraction. Higher 
ejection fraction leads to better cardiac output and better perfusion of sensitive organs 
like kidney, brain etc, so it decrease mortality significantly. According to studies ejection 
fraction interacts with mean arterial pressure for predicting mortality, so it is an 
independent risk factor of survival in patients with HF (Adamopoulos, Zannad et al. 
2007). In both Whites and Blacks, NYHA classification is a risk factor for prediction of 
outcome. NYHA classification is given for assessing the severity of HF and functionality 
of patient with HF. As the classification advances from class II to class IV, the functional 
status of the patients decreases, patient becomes bedridden, outcome will be worst in 
these patients (Hurst, Morris et al. 1999). Studies also suggest that systolic blood pressure 
is a risk predictor for outcome of HF. High systolic blood pressure, but within normal 
range increases the survival of patients with HF irrespective of etiology for HF (Lee, 
Chen et al. 2006; Adamopoulos, Zannad et al. 2007). However, in this study, systolic 
blood pressure is a significant risk predictor in Blacks but not in Whites. 
 It has been postulated that use of beta blocker in HF decreases the mortality in HF 
patients. However, according to the univariate analsysis of this study, beta blocker 
increases the risk of positive outcome in both Whites and Blacks. Although, use of 
carvedilol has been prove effective in both the races in decreasing the mortality.(Yancy, 
Fowler et al. 2001) This effect can be due to unadjustment of beta blocker use with other 
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variables and discussed in more detail later in this chapter. In Blacks use of furosemide 
increases the risk for adverse HF outcome and this might be due to relative hypovolemia 
in Black population. Apart from that Aldosterone blocker is more effective in Whites 
than Blacks because Blacks have relatively low level of renin-angiotensin-aldosterone 
system level and that is the reason that aldosterone blockers are not much effective in 
Blacks than in Whites. Also, ACE inhibitors are less effective in Blacks and this is due to 
above mentioned reason plus ACE gene polymorphisms in Whites and Blacks. (Bloem, 
Manatunga et al. 1996) Studies have suggested that digoxin has favorable effect in 
decreasing hospitalization and mortality from HF. (1997; Mathew, Wittes et al. 2005) 
 According to multivariate model, in Whites important predictors are male gender, 
hypertension, history of ventricular arrhythmias, AICD, EF%, NYHA class, beta blocker, 
Aldosterone blocker, furosemide, and lymphocyte when adjusted for other co-variates 
used in univariate analysis. For Blacks important factors are age, history of PTCA, 
dyslipidemia, history of depression, AICD, EF%, systolic blood pressure, NYHA class, 
beta-blocker, torsemide, and digoxin when adjusted for other co-variates. 
 According to univariate analysis AICD was decreasing the adverse outcome only 
in Blacks, but when adjustment for other variables was performed the same finding was 
observed in Whites as well. High ejection fraction is associated with decrease risk for 
adverse outcome in both races and high NYHA class is associated with worst outcome in 
both races. As mentioned above, carvedilol decreases the mortality in both Whites and 
Blacks and in this study when adjustment for other variables was performed use of beta-
blockers proves to increase survival in both races. In Whites use of furosemide is 
associated with increases adverse outcomes and it seems to an insignificant risk factor in 
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Blacks. It has been suggested that furosemide has adverse renal effect at high optimal 
doses and apart from that it can prolong the hospitalization (Peacock, Costanzo et al. 
2008). Also aggressive use of diuretics in the treatment of HF results in electrolyte and 
volume depletion, arrhythmias, hypotension and worsening renal function.(Goebel and 
Van Bakel 2008) Apart from that torsemide increases the mortality in Blacks for above 
mentioned reasons. According to DIG trial, digoxin proved to increase survival in 
patients with HF; however, there was a racial difference in this medication effects. An 
increased risk of adverse outcomes was observed in Blacks, when use of digoxin was 
adjusted for other variables, but not in Whites. These differences of medication effects 
could explained by the different genetic response to medications in Blacks and Whites 
(Bloem, Manatunga et al. 1996; Small, Wagoner et al. 2002). 
 In this study history of PTCA is important risk factor for Blacks but not for 
Whites. Study have been reported about the PTCA and high mortality in African 
American. According this study, at 5 year follow up, African American have worst 
clinical outcome who have undergone PTCA compared to Whites (Pradhan et al. 2008). 
Several studies have shown that depression is an independent risk factor for both 
ischemic heart disease and HF. This is because tricyclic antidepressant used for treatment 
of depression also have class IA antiarrythmic properties and found to increase the 
mortality in these patients (1989; Carney, Freedland et al. 1997). In this study, depression 
is an important risk factor for Blacks, but not for Whites when depression was adjusted 
for other variables. In Blacks, obesity and dyslipidemia are major problems and they are 
important risk factors for adverse outcomes.  
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 This study shows that Blacks have higher survival rate than Whites. There are 
several studies reporting on survival rates in Black and White patients with HF. Data of 
these studies are controversial as Blacks seems to have similar, higher or lower mortality 
rates compared to Whites (Dries, Exner et al. 1999; Rathore, Foody et al. 2003). 
According to study by Dries et al., this difference is due to differences in the severity, 
causes and management of HF, the prevalence of coexisting conditions, and socio 
economic factors. According to study by Rathore et al. Blacks have lower mortality risk 
than Whites. The study was conducted retrospectively on Medicare beneficiary 
hospitalized patients. However, in this study Blacks had higher hospitalization rate, but 
lower mortality rate compared to Whites.  
 There are several limitations in this study among one was, a retrospective study, 
so it was difficult to find the missing data values in this dataset. Furthermore, the power 
is low and because of that the finding of this study cannot be generalized to general 
population. Although the findings were adjusted for potential confounders, the possibility 
that these findings could be explained by interaction of other variables that was not taken 
into account cannot be excluded. 
Recommendations: 
 As explained above there may be genetic polymorphism in Whites and Blacks and 
that might be the reason for different treatment response in these two races, so large study 
required to explore this finding. Large datasets are available for other cardiac diseases 
such as myocardial infarction, hypertension and there are studies reported on the 
variation in the etiology, pathophysiology and treatment responses in Whites and Blacks.  
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 Health care resources should be more easily accessible as HF is a condition which 
can be deteriorated very fast. Apart from that, proper counseling should be available for 
all the patients without any racial discrimination.  
 Heart transplant is a major procedure, very expensive, and every year very few 
transplants occur. Also donor organs are very limited as there are few living donors for 
heart transplant. Thus, it would be wise more detailed data to be collected regarding heart 
transplant, in order for physicians to better understand possible racial differences in this 
outcome and also if race is a prognostic factor for post transplant survival.    
 In conclusion, there is no significant difference in the combined outcome (death, 
transplant, emergency transplant, and LVAD) of HF between Whites and Blacks. There 
are differences regarding the risk factors which are more prominent in each race, 
however, some of them are common between the two races. Further studies on larger 
population are required to establish race as a significant risk factor for predicting the 
outcome in HF.  
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Appendices 
 
Appendix A. Clinical Characteristics of Heart Failure in Whites and Blacks. 
Variable Whites Blacks P-value 
Gender 
Male 
Female 
 
75.9% 
24.1% 
 
56.7% 
43.3% 
<0.001 
 
Smoking 
Never Smoke 
Smoker 
Former Smoker 
 
44.9% 
18.9% 
36.1% 
 
51.0% 
23.8% 
25.2% 
<0.05 
Alcohol Consumption 
No Drinker 
Drinker 
Former Drinker 
 
64.3% 
23.4% 
12.2% 
 
60.6% 
27.3% 
12.1% 
0.621 
Primary Cause of HF 
Ischemic 
Idiopathic 
 
 
52.1% 
47.9% 
 
 
22.3% 
77.7% 
 
<0.001 
History of Myocardial Infarction 
Yes 
No 
 
46.2% 
53.8% 
 
20.3% 
79.7% 
<0.001 
History of CABG 
Yes 
No 
 
31.0% 
69.0% 
 
9.6% 
90.4% 
<0.001 
History of PTCA 
Yes 
No 
 
21.9% 
78.1% 
 
9.6% 
90.4% 
<0.001 
Hypertension 
Yes 
No 
 
52.5% 
47.5% 
 
75.7% 
24.3% 
<0.001 
Diabetes 
Yes 
No 
 
35.1% 
64.9% 
 
38.9% 
61.1% 
0.385 
Dislipidemia 
Yes 
No 
 
54.8% 
45.2% 
 
39.6% 
60.4% 
0.001 
History of Chronic Lung Disease 
No 
Yes 
No Mention 
 
76.4% 
22.2%% 
1.4% 
 
77.8% 
21.2% 
1.0% 
0.879 
History of Sleep Apnea 
No 
Yes 
No Mention 
 
78.5% 
16.2% 
5.3% 
 
80.9% 
16.2% 
2.9% 
0.451 
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History of CPAP 
No 
Yes 
No Mention 
 
83.6% 
10.7% 
5.7% 
 
88.3% 
8.2% 
3.6% 
0.346 
Thyroid Disorder 
No Disorder 
Hyperthyroidism 
Hypothyroidism 
 
80.4% 
18.2% 
1.4% 
 
81.9% 
16.6% 
1.5% 
0.898 
Depression 
No 
Yes 
No Mention 
 
70.6% 
26.0% 
3.5% 
 
79.8% 
17.7% 
2.5% 
 
0.073 
History of CVA 
No 
Yes 
 
87.2% 
12.8% 
 
80.4% 
19.6% 
<0.05 
Cancer 
No 
Yes 
 
89.3% 
10.7% 
 
90.8% 
9.2% 
0.598 
F/H of Idiopathic 
Cardiomyopathy 
No 
Yes 
No Mention 
 
 
60.0% 
20.0% 
20.0% 
 
 
65.3% 
16.8% 
17.9% 
0.493 
F/H of Dilated Cardiomyopathy 
No 
Yes 
No Mention 
 
75.5% 
5.0% 
19.4% 
 
70.0% 
12.2% 
17.3% 
<0.05 
Atrial Arrhythmias 
No Atrial Arrhythmias 
Paroxysmal Atril 
Fibrillation/Fluter 
Chronic Atrial 
Fibrillation/Flutter 
Atrial Tachycardia 
Paroxysmal Supraventricular 
Tachycardia 
 
52.9% 
16.6% 
20.4% 
1.7% 
3.1% 
 
5.2% 
 
56.4% 
17.8% 
14.4% 
2.0% 
3.5% 
 
5.9% 
0.698 
Ventricular Arrhythmias 
No  
Yes 
No Mention 
 
50.7% 
44.1% 
5.2% 
 
54.1% 
38.3% 
7.7% 
0.312 
 
Device 
No 
Yes 
 
31.5% 
68.5% 
 
37.1% 
62.9% 
0.153 
AICD 
No 
Yes 
 
72.0% 
28.0% 
 
69.5% 
30.5% 
0.517 
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BivPace/Device 
No 
Yes 
 
65.0% 
35.0% 
 
70.4% 
29.6% 
0.173 
Biv Pace 
No 
Yes 
 
79.6% 
20.4% 
 
83.3% 
16.7% 
0.607 
Outcome 
Yes  
No 
 
34.6% 
65.4% 
 
28.9% 
71.1% 
0.169 
Age 55.68±11.39 49.22±13.21 <0.001 
Height (Inches) 69.83±3.58 66.93±3.95 <0.001 
Weight (LB) 208.13±47.67 195.38±41.62 0.133 
Heart Rate at visit 74.59±12.85 79.89±15.85 <0.001 
Systolic BP 113.32±19.12 119.06±19.32 <0.001 
Diastolic BP 72.06±11.40 74.81±10.08 0.172 
NYHA at Visit 2.43±0.74 2.46±0.70 0.598 
EF% 21.50±11.17 17.89±9.4 <0.001 
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Appendix B. Drugs and Laboratory profiles in Whites and Blacks 
Variable Whites Blacks P-value 
ACE-I 75.0% 66.1% <0.05 
ARB 19.5% 24.7% 0.136 
Beta-Blocker 88.8% 89.8% 0.708 
Statin 54.7% 34.0% <0.001 
Ezetimibe 3.0% 0% 0.251 
Allopurinol 9.4% 6.1% 0.146 
Aldosteron Blocker 38.6% 50.6% <0.01 
Furosemide 60.6% 65.3% 0.245 
Bumetanode 0.9% 2.0% 0.236 
Torsemide 19.8% 26.1% 0.069 
Metolazone 5.6% 6.5% 0.642 
Hydrochlorothiazide 4.4% 4.5% 0.970 
Digoxin 49.7% 54.3% 0.275 
Aspirin 59.0% 51.2% 0.386 
Clopidogril 8.1% 4.7% 0.463 
Oral Nitrates 12.0% 14.0% 0.747 
Calcium-Channel Antagonist 13.0% 12.8% 0.926 
Antiarrhythmics 33.1% 26.9% 0.109 
NSAID 5.0% 7.0% 0.637 
Warfarin 56.4% 58.1% 0.850 
Antidepressant 36.0% 18.6% <0.05 
Antianxiety 20.0% 4.7% <0.05 
Insulin 10.0% 9.35% 0.898 
Sulfonylurea 13.0% 11.6% 0.821 
Biguanide 7.0% 4.7% 0.596 
Thiazolinidiones 7.0% 2.3% 0.265 
Other Drugs 67.7% 66.7% 0.907 
WBC(×10E3) 10.03±40.56 7.05±2.28 0.255 
RBC(×10E6) 4.38±0.53 4.48±0.71 0.406 
RDW% 14.63±2.2 17.69±15.63 0.085 
Hgb 13.64±2.66 12.97±1.80 0.001 
Hct% 39.19±6.1 38.82±5.97 0.484 
Platelet(×10E3) 228.97±71.98 251.49±87.08 0.001 
Mean Platelet Volume 8.72±1.06 9.26±1.09 0.01 
Lymphocyte% 23.40±7.8 26.45±9.02 <0.001 
Na+ 137.24±3.22 137.99±3.1 <0.01 
K+ 4.15±0.54 3.95±0.49 <0.001 
CO2 27.77±6.1 27.38±2.7 0.697 
Glucose 119.34±50.55 112.84±39.53 0.096 
BUN 22.02±12.14 22.97±19.27 0.470 
Creatinine 1.29±0.71 1.45±1.18 0.50 
Protein Total 7.10±0.64 7.33±0.73 0.176 
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Albumin 3.7±0.40 3.68±0.46 0.661 
Uric Acid 8.3±0.88 8.5±1.1 0.017 
CPK 113.56±96.75 181.0±154.86 0.202 
CK-MB 4.71±8.38 2.38±0.744 0.128 
Troponin-I 1.2±3.65 0.15±0.32 0.378 
BNP 649.51±845.86 981.37±1171.99 0.046 
Total cholesterol 158.60±37.82 161.88±43.14 0.361 
Triglyceride 168.49±138.24 114.79±132.50 <0.001 
HDL 38.67±12.27 44.65±13.67 0.099 
LDL 88.94±39.33 103.28±51.18 0.238 
TSH 3.43±1.05 4.73±1.69 0.381 
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Table C. Clinical Characteristics by Outcome of Heart Failure. 
Variable Outcome 
Positive 
Outcome 
negative 
P-value 
Gender 
Male 
Female 
 
75.2% 
24.8% 
 
65.6% 
34.4% 
<0.05 
Race 
White 
Black 
 
60.6% 
39.4% 
 
54.2% 
45.8% 
0.169 
Smoking 
Never Smoker 
Smoker 
Former Smoker 
 
41.8% 
19.6% 
38.6% 
 
43.8% 
25.2% 
31.0% 
0.208 
Alcohol Consumption 
No Drinker 
Drinker 
Former Drinker 
 
65.2% 
20.0% 
14.8% 
 
55.6% 
32.8% 
11.6% 
<0.05 
Primary Cause of Heart Failure 
Ischemic 
Idiopathic 
 
46.0% 
54.0% 
 
 
37.2% 
62.8% 
 
<0.05 
History of Myocardial Infarction 
Yes 
No 
 
39.6% 
60.4% 
 
34.4% 
65.6% 
0.251 
History of CABG 
Yes 
No 
 
21.6% 
78.4% 
 
23.8% 
76.2% 
0.588 
History of PTCA 
Yes 
No 
 
18.5% 
81.5% 
 
16.8% 
83.2% 
0.635 
Hypertension 
Yes 
No 
 
59.7% 
40.3% 
 
65.7% 
34.3% 
0.210 
Diabetes 
Yes 
No 
 
38.2% 
61.8% 
 
38.6% 
61.4% 
0.937 
Dislipidemia 
Yes 
No 
 
52.5% 
47.5% 
 
47.1% 
52.9% 
0.283 
History of Chronic Lung Disease 
No 
Yes 
No Mention 
 
70.2% 
28.6% 
1.2% 
 
 
78.8% 
20.0% 
1.2% 
0.129 
History of Sleep Apnea   <0.001 
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No 
Yes 
No Mention 
75.8% 
14.3% 
9.9% 
80.9% 
18.0% 
1.2% 
History of CPAP 
No 
Yes 
No Mention 
 
82.4% 
6.9% 
10.7% 
 
87.9% 
10.9% 
1.2% 
<0.001 
Thyroid Disorder 
No Disorder 
Hyperthyroidism 
Hypothyroidism 
 
78.2% 
17.3% 
4.5% 
 
82.5% 
17.5% 
0% 
<0.01 
Depression 
No 
Yes 
No Mention 
 
66.2% 
27.5% 
6.2% 
 
78.5% 
20.3% 
6.2% 
<0.01 
History of CVA 
No 
Yes 
 
83.8% 
16.2% 
 
86.4% 
13.6% 
0.459 
Cancer 
No 
Yes 
 
85.0% 
15.0% 
 
91.0% 
9.0% 
0.064 
F/H of Idiopathic 
Cardiomyopathy 
No 
Yes 
No Mention 
 
60.4% 
23.3% 
16.4% 
 
57.5% 
17.0% 
25.5% 
0.055 
F/H of Dilated Cardiomyopathy 
No 
Yes 
No Mention 
 
76.6% 
8.9% 
14.67% 
 
64.9% 
9.4% 
25.7% 
<0.05 
Atrial Arrhythmias 
No Atrial Arrhythmias 
Paroxysmal Atril 
Fibrillation/Flutter 
Chronic Atrial 
Fibrillation/Flutter 
Atrial Tachycardia 
Paroxysmal Supraventricular 
Tachycardia 
No Mention 
 
 
59.9% 
14.8% 
19.1% 
3.1% 
0% 
 
3.1% 
 
48.6% 
17.8% 
19.7% 
1.2% 
5.8% 
 
6.9% 
<0.01 
Ventricular Arrhythmias 
No  
Yes 
No Mention 
 
43.2% 
53.1% 
3.7% 
 
50.2% 
41.0% 
8.8% 
<0.05 
Device   0.09 
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No 
Yes 
35.2% 
64.8% 
27.8% 
72.2% 
AICD 
No 
Yes 
 
78.3% 
21.7% 
 
66.5% 
33.5% 
<0.01 
BivPace/Device 
No 
Yes 
 
66.0% 
34.0% 
 
62.5% 
37.5% 
0.433 
Biv Pace 
No 
Yes 
 
76.7% 
23.3% 
 
89.7% 
10.3% 
0.162 
Age 51.52±14.27 53.18±11.45 0.159 
Height (Inches) 69.98±3.8 68.52±4.37 0.143 
Weight (LB) 198.95±38.79 201.62±51.42 0.802 
Heart Rate at visit 79.74±15.61 76.22±13.13 <0.05 
Systolic BP 110.92±19.68 116.25±18.67 <0.01 
Diastolic BP 70.41±12.43 72.21±9.2 0.206 
NYHA at Visit 2.80±0.72 2.37±0.63 <0.001 
EF% 17.05±8.87 19.77±9.03 <0.01 
 
Outcomes = Death or Emergency Transplant or Transplant or LVAD 
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Table D. Drugs and Laboratory Profile for Outcome of Heart Failure. 
Variable Outcome 
Positive 
Outcome 
negative 
P-value 
ACE-I 69.7% 72.2% 0.557 
ARB 21.8% 20.7% 0.782 
Beta-Blocker 76.4% 95.1% <0.001 
Statin 43.9% 45.0% 0.818 
Ezetimibe 2.3% 3.4% 0.763 
Allopurinol 8.5% 6.0% 0.3 
Aldosteron Blocker 51.5% 41.3% <0.05 
Furosemide 57.6% 64.2% 0.149 
Bumetanode 0.6% 1.4% 0.415 
Torsemide 34.5% 17.5% <0.001 
Metolazone 9.1% 4.9% 0.065 
Hydrochlorothiazide 4.8% 4.8% 0.778 
Digoxin 66.7% 44.5% <0.001 
Aspirin 61.4% 39.3% 0.067 
Clopidogril 7.0% 3.4% 0.521 
Oral Nitrates 15.9% 6.9% 0.252 
Calcium-Channel Antagonist 9.5% 9.5% 0.093 
Antiarrhythmics 38.8% 27.3% <0.01 
NSAID 4.5% 0% 0.244 
Warfarin 56.8% 55.2% 0.89 
Antidepressant 27.3% 31.0% 0.728 
Antianxiety 13.6% 10.3% 0.676 
Insulin 9.1% 13.8% 0.529 
Sulfonylurea 9.1% 10.3% 0.859 
Biguanide 2.3% 13.8% 0.057 
Thiazolidinedione 0% 10.3% <0.05 
Other Drugs 70.5% 75.0% 0.675 
WBC(×10E3) 7.67±2.73 7.42±2.18 0.363 
RBC(×10E6) 4.22±0.67 4.49±0.51 0.256 
RDW% 15.3±2.4 14.9±2.3 0.684 
Hgb 13.33±2.48 13.27±1.77 0.165 
Hct% 38.79±6.36 39.17±5.58 0.262 
Platelet(×10E3) 229.22±71.84 244.42±85.01 <0.05 
Mean Platelet Volume 9.00±0.99 8.74±1.26 0.540 
Lymphocyte% 21.85±8.15 25.40±7.44 <0.001 
Na+ 136.5±3.21 138.03±3.1 <0.001 
K+ 4.05±0.522 4.07±0.54 0.597 
CO2 27.23±2.52 26.70±2.98 0.419 
Glucose 114.71±40.75 117.12±47.05 0.265 
BUN 25.80±13.87 21.38±16.81 <0.01 
Creatinine 1.58±1.38 1.30±0.72 <0.05 
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Protein Total 7.06±0.85 7.12±0.48 0.154 
Albumin 3.58±0.46 3.71±0.34 0.181 
Uric Acid 8.4±1.69 8.4±0.43  
CPK 107.67±49.34 90.50±53.03 0.971 
CK-MB 2.67±2.29 3.00±1.41 0.438 
Troponin-I 0.06±0.1 0.03 0.725 
BNP 1.32±1331.61 6.5±843.57 <0.001 
Total cholesterol 157.00±44.61 161.04±38.45 0.318 
Triglyceride 123.25±73.45 155.29±158.65 <0.05 
HDL 37.30±10.95 41.73±15.32 0.116 
LDL 98.15±48.69 97.47±45.85 0.517 
TSH 4.07±1.17 3.77±1.41 0.88 
 
 
 
 
 
